Canada Markets open in 2 hrs 32 mins

Filament Health Corp. (FLHLF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.05840.0000 (0.00%)
At close: 09:54AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.0584
Open0.0584
BidN/A x N/A
AskN/A x N/A
Day's Range0.0584 - 0.0584
52 Week Range0.0506 - 0.3680
Volume2,000
Avg. Volume12,077
Market Cap9.627M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Psyence Group Completes Export of Psilocybin Mushrooms to Canada

    TORONTO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) has successfully exported psilocybin mushrooms to Psilo Scientific Ltd. in Canada. Psilo Scientific, a wholly owned subsidiary of Filament Health Corp., is an exclusively natural psychedelic drug discovery and extraction company. Psyence received a Health Canada import permit obtained by Psilo Scientific in March 2022. The psilocybin mushrooms have now been received at Psilo Sci

  • CNW Group

    FILAMENT HEALTH AND ATMA JOURNEY CENTERS ANNOUNCE 14 SUBJECTS DOSED IN HEALTH CANADA-APPROVED PSILOCYBIN CLINICAL TRIAL

    Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, and ATMA Journey Centers ("ATMA"), a company focused on delivering effective and innovative experiences that leverage the potential of psychedelic medicine, today announced the recent dosing of 14 healthy subjects with Filament's natural psilocybin drug candidate in a Health Canada-approved clinical trial as part of ATMA's psychedelic-assisted th

  • CNW Group

    FILAMENT HEALTH APPOINTS NEW MEMBERS TO BOARD OF DIRECTORS AND ADVISORY COUNCIL

    Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced the appointment of Dr. Konstantin Adamsky of Negev Capital to its Board of Directors, and Jeff Chilton of Nammex to the Company's Advisory Council.